Saba Capital Amends BlackRock Health Sciences Trust Filing

TL;DR

Saba Capital updated their stake in BlackRock Health Sciences Term Trust. Watch this space.

AI Summary

Saba Capital Management, L.P. filed an amendment (13D/A) on May 21, 2024, regarding their holdings in BlackRock Health Sciences Term Trust. This filing indicates a change in their beneficial ownership, though specific new percentages or dollar amounts are not detailed in this excerpt. The filing is an update to their previous Schedule 13D.

Why It Matters

This filing signals a potential shift in significant shareholder activity for BlackRock Health Sciences Term Trust, which could influence the trust's future strategy or performance.

Risk Assessment

Risk Level: medium — Schedule 13D/A filings often indicate significant shareholder activity, which can lead to increased volatility or strategic changes in the subject company.

Key Players & Entities

• Saba Capital Management, L.P. (company) — Filer of the Schedule 13D/A
• BlackRock Health Sciences Term Trust (company) — Subject company of the filing
• Michael D'Angelo (person) — Contact person for Saba Capital Management, L.P.

FAQ

Key Financial Figures

• $0.001 — rust (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securiti
• $307,213,554 — ported herein. A total of approximately $307,213,554 was paid to acquire the Common Shares r

Filing Documents

• formsc13da.htm (SC 13D/A) — 59KB
• 0001062993-24-010852.txt ( ) — 61KB

is hereby amended and supplemented as follows

Item 4 is hereby amended and supplemented as follows: The Reporting Persons issued the investor presentation (the "Investor Presentation") attached hereto as Exhibit 4 to shareholders (such exhibit to be deemed incorporated by reference in its entirety into this Item 4) providing their views on the Issuer and its Board, including value-unlocking steps it believes the Issuer should take. Item 5. INTEREST IN SECURITIES OF THE ISSUER (a) See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of Common Shares and percentages of the Common Shares beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 106,514,258 shares of common stock outstanding as of 12/31/23, as disclosed in the company's N-CSR filed 3/6/24 (b) See rows (7) through (10) of the cover pages to this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. (c) The transactions in the Common Shares effected in the last sixty days by the Reporting Persons, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference (d) The funds and accounts advised by Saba Capital have the right to receive the dividends from and proceeds of sales from the Common Shares. (e) Not applicable. Item 7. MATERIAL TO BE FILED AS EXHIBITS Exhibit 4: Investor Presentation, incorporated herein by reference to the DFAN14A filed with the Securities and Exchange Commission on May 20, 2024. CUSIP No. 09260E105 SCHEDULE 13D/A Page 6 of 7 Pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: May 21, 2024 SABA CAPITAL MANAGEMENT, L.P. By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Chief Compliance Officer SABA CAPITAL MANAGEMENT GP, LLC By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Authorized Signatory BOAZ R. WEINSTEIN By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Attorney-in-fact* * Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823 CUSIP No. 09260E105 SCHEDULE 13D/A Page 7 of 7 Pages Schedule A This Schedule sets forth information with respect to each purchase and sale of Common Shares which were effectuated by Saba Capital in the last sixty days. All transactions were effectuated in the open market through a broker. Trade Date Buy/Sell Shares Price 3/26/2024 Buy 129,372 16.32 3/28/2024 Buy 16,297 16.33 4/1/2024 Buy 46,421 16.34

View Full Filing

View this SC 13D/A filing on SEC EDGAR